Amsel Medical
The new standard of care for minimally invasive transfixing/occluding procedures
The new standard of care for minimally invasive transfixing/occluding procedures
Amsel Medical is a healthcare startup founded in 2011 and based in the United States. The company has developed a unique mechanical surgical clamping technology delivered through a fine, minimally invasive, 18 G needle for clamping of blood vessels, ducts, arteries, and veins. This provides secure occlusion similar to that of a transfixion suture. Amsel Medical's product, SCureClamp, incorporates iDOT’s anchoring feature which secures the implant in place and eliminates slippage. Physicians can use it to occlude vessels of varying sizes, types, and wall thickness. The last investment in the company was a $4.00M Convertible Note investment at 01 January 2022. While the specific investors behind this latest funding round are not mentioned, the company's innovative approach to minimally invasive transfixing/occluding procedures in the healthcare industry signifies potential for growth and advancement in surgical technology.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Convertible Note | $4.00M | - | 01 Jan 2022 | |
| Convertible Note | $1.45M | 4 |
|
30 Jan 2021 |
| Angel Round | $1.60M | 1 |
|
21 Nov 2018 |
| Seed Round | $2.70M | - | 06 Jul 2011 |
No recent news or press coverage available for Amsel Medical.
We care about your data, and we'd love to use cookies make your experience better.
